Prostate News and Research

RSS

Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive

New research published in today's issue of the Archives of Internal Medicine (Vol. 170, No. 5), by an investigator at The Cancer Institute of New Jersey and colleagues at Memorial Sloan-Kettering Cancer Center in New York, shows that the type of specialist that men with localized prostate cancer see can influence the form of therapy they ultimately receive.

9 Mar 2010

Prostate cancer: Therapy depends on consulted specialty

Men who visit a radiation oncologist appear more likely to receive radiation therapy for prostate cancer, whereas men who consult with a urologist with or without a medical oncologist are treated more frequently with hormone therapy, watchful waiting or a radical prostatectomy, according to a report in the March 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

9 Mar 2010

Nanoparticles: Targeted cancer therapy

Another weapon in the arsenal against cancer: Nanoparticles that identify, target and kill specific cancer cells while leaving healthy cells alone.

9 Mar 2010

Prostate-specific dietary supplements discouraged during radiation therapy treatments: Study

Prostate-specific dietary supplements should not be taken during radiation therapy treatments because they have been shown to increase the radiosensitivity of normal prostate cell lines, leading to normal tissue complications, according to a study in the March issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology.

8 Mar 2010

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the fourth quarter and year ended December 31, 2009.

8 Mar 2010

DiagnoCure: Global studies confirm clinical utility of PROGENSA PCA3 test

DiagnoCure, Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that the clinical utility of the PROGENSA(R) PCA3 test, developed and commercialized by its partner Gen-Probe, was confirmed in two large worldwide studies, conducted in a subset of patients in GlaxoSmithKline's REDUCE trial of dutasteride. The results demonstrate that PCA3 can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy and can predict the risk of having an aggressive cancer.

8 Mar 2010

Necessity of repeat biopsy in suspected prostate cancer: Gen-Probe's PROGENSA PCA3 assay can help determine

Gen-Probe's PROGENSA® PCA3 assay can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy, according to data from the two largest studies to date of the molecular urine test. The studies were presented last week at the American Society of Clinical Oncology's (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco.

8 Mar 2010

AHF’s Magic Johnson ‘Testing America’ Tour arrives in Jacksonville to offer free HIV testing

AHF’s Magic Johnson ‘Testing America’ Tour, a six month, 48 state national cross country HIV testing tour, arrives in Jacksonville, Florida today and will offer free HIV testing, along with local partner JASMYN and APEL Health Services, today Saturday, March 6th at APEL Health Services, 5353 Soutel Dr., from 11:00 am to 2:00 pm.

7 Mar 2010

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The results were presented in a General Poster Session today at the 2010 American Society of Clinical Oncology's Genitourinary Cancers Symposium in San Francisco, CA.

6 Mar 2010

American Cancer Society stresses importance of educating patients to risk of prostate screening

The Los Angeles Times: New prostate cancer screening guidelines issued Wednesday by the American Cancer Society "emphasize that physicians should better educate men about both the risks and benefits of using the PSA test for screening. They also call for cutbacks in the use of digital rectal exams to find tumors and recommend the end of mass prostate-screening programs at health fairs and other sites."

5 Mar 2010

America's Prostate Cancer Organizations release shared perspective on screening and treatment

America's Prostate Cancer Organizations today released the full text of written testimony to the House Committee on Oversight and Government Reform. The Committee will be holding a hearing on "Prostate Cancer: New Questions About Screening and Treatment" on March 4, 2010.

5 Mar 2010

Men should discuss risks, benefits with doctor before undergoing prostate-cancer screening

Men who undergo prostate-cancer screening should discuss with a doctor the uncertainties, risks and benefits of the test before it is performed, says Edward Partridge, M.D., president-elect of the American Cancer Society National Board of Directors and director of the University of Alabama at Birmingham Comprehensive Cancer Center.

5 Mar 2010

Health Discovery delivers letter of gratitude and support to Congressman Edolphus Towns for holding congressional hearing

Health Discovery Corporation announced today that it delivered a letter of gratitude and support to Congressman Edolphus Towns, Chairman of the House Committee on Oversight and Government Reform for holding today, March 4, 2010, a congressional hearing on “Prostate Cancer: New Questions About Screening and Treatment.”

5 Mar 2010

Heartburn drug Kapidex to be marketed under new name Dexilant

The U.S. Food and Drug Administration has approved a name change for the heartburn drug Kapidex (dexlansoprazole) to avoid confusion with two other medications – Casodex and Kadian. Effective in late April 2010, Takeda Pharmaceuticals North America Inc. will market Kapidex under the new name Dexilant.

4 Mar 2010

Accurate, life-saving diagnostic tools needed for screening and prevention of prostate cancer, says AdMeTech

AdMeTech President and CEO Dr. Faina Shtern told the U.S. House Committee on Oversight and Government Reform that a major national commitment is needed to create accurate, life-saving diagnostic tools for prostate cancer and end what she called "the prostate cancer crisis."

4 Mar 2010

Testimony emphasizes that health reform bills eliminate prostate cancer screening

The House Committee on Oversight and Government Reform, chaired by Congressman Edolphus Towns, will hold a hearing entitled: "Prostate Cancer: New Questions About Screening and Treatment."

4 Mar 2010

Arc radiotherapy treatments: Breakthrough in image-guided targeting of prostate tumors

Researchers in the US and Denmark have made a breakthrough in image-guided targeting of prostate tumors during arc radiotherapy treatments. In research partially supported by Varian Medical Systems, physicists at Stanford University (California, USA) and Aarhus University Hospital (Aarhus, Denmark) have devised a method for 'real-time' tracking of the prostate motion using Varian's On-Board Imager® that shows promise in paving the way for advanced clinical treatments.

4 Mar 2010

Prostate cancer screening: Another set of new guidelines adds to the confusion

Members of America's Prostate Cancer Organizations are concerned that the issuance this morning of yet another set of new guidelines on screening for prostate cancer is only adding to the confusion most men already feel about whether they should or shouldn't be tested for the most common form of cancer in American men.

4 Mar 2010

PCF: PSA screening remains valuable tool for identifying potential prostate disease

Responding to continued debate over PSA screening, and today’s American Cancer Society statement, the Prostate Cancer Foundation reiterated its position that PSA screening remains a valuable tool, in combination with other tools, for identifying potential prostate disease, including cancer.

4 Mar 2010

$Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer$

Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer

Sanofi-aventis announced today results from a Phase 3 trial which demonstrated cabazitaxel, an investigational compound, plus prednisone/prednisolone significantly improved overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease progressed following treatment with docetaxel-based chemotherapy.

3 Mar 2010

Prostate News and Research

Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive

Prostate cancer: Therapy depends on consulted specialty

Nanoparticles: Targeted cancer therapy

Prostate-specific dietary supplements discouraged during radiation therapy treatments: Study

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

DiagnoCure: Global studies confirm clinical utility of PROGENSA PCA3 test

Necessity of repeat biopsy in suspected prostate cancer: Gen-Probe's PROGENSA PCA3 assay can help determine

AHF’s Magic Johnson ‘Testing America’ Tour arrives in Jacksonville to offer free HIV testing

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

American Cancer Society stresses importance of educating patients to risk of prostate screening

America's Prostate Cancer Organizations release shared perspective on screening and treatment

Men should discuss risks, benefits with doctor before undergoing prostate-cancer screening

Health Discovery delivers letter of gratitude and support to Congressman Edolphus Towns for holding congressional hearing

Heartburn drug Kapidex to be marketed under new name Dexilant

Accurate, life-saving diagnostic tools needed for screening and prevention of prostate cancer, says AdMeTech

Testimony emphasizes that health reform bills eliminate prostate cancer screening

Arc radiotherapy treatments: Breakthrough in image-guided targeting of prostate tumors

Prostate cancer screening: Another set of new guidelines adds to the confusion

PCF: PSA screening remains valuable tool for identifying potential prostate disease

Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News